Breast cancer with ER/PR, and HER2 overexpression, as well as triple negative breast cancer accounts for approximately 60, 20 and 20% of the total breast cancer cases, respectively [5]. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.